Covid-19 roundup: Biden out­lines virus plan, names Rick Bright to task force; Arc­turus reads out pos­i­tive Phase I/II vac­cine da­ta 

Last year
Coronavirus

New­ly Nas­daq-list­ed Cal­lid­i­tas surges af­ter lead kid­ney drug hits pri­ma­ry end­point

Last year
R&D

Now that Bio­gen’s ad­u­canum­ab team and the FDA’s Bil­ly Dunn have been bat­tered by a gamut of an­gry ex­perts, the an­a­lysts are weigh­ing in

Last year
FDA+

Karin Rosén moves on from GSK, now play­ing dual roles at Hori­zon; Gilead looks to Jared Baeten to take com­mand of HIV strat­e­gy

Last year
Peer Review

Sanofi hits the brakes on a top piv­otal pro­gram fol­low­ing 'new ad­verse events'

Last year
R&D

Cit­ing pan­dem­ic, Sarep­ta de­fers much-an­tic­i­pat­ed DMD gene ther­a­py PhI­II, will head to reg­u­la­tors af­ter 10-per­son study

Last year
Cell/Gene Tx
FDA+

No­vo Nordisk bolts on a ‘holy grail’ oral de­liv­ery plat­form in $1.8B buy­out

Last year
Deals

Covid-19 roundup: So­ri­ot — vac­cine could be ready by year's end; WHO omits remde­sivir from de­vel­op­ing coun­tries plan

Last year
Coronavirus

In­spired by ASH da­ta, Mer­ck­'s Roger Perl­mut­ter swoops in with a $2.75B ROR1 buy­out aimed at beef­ing up the can­cer pipeline

Last year
Deals

Ver­tex, fresh off an R&D miss, flash­es da­ta sug­gest­ing their sick­le cell CRISPR ther­a­py is work­ing

Last year
R&D
Cell/Gene Tx

FDA in­sid­er re­view of­fers a stel­lar en­dorse­ment for Bio­gen’s con­tro­ver­sial ad­u­canum­ab to treat Alzheimer’s — but sta­tis­ti­cal analy­sis mars the pic­ture

Last year
FDA+

An elec­tion night bereft of an­swers quells bio­phar­ma's 'worst-case' fears — an­a­lysts

Last year
Pharma
FDA+

Covid-19 roundup: Ox­ford in­ves­ti­ga­tor sees 's­mall chance' for vac­cine roll­out by year end; Fo­s­un fol­lows Pfiz­er with fi­nal choice of BioN­Tech can­di­date

Last year
Coronavirus

The End­points poll: A large ma­jor­i­ty of bio­phar­ma ex­ecs turn thumbs down on Bio­gen's con­tro­ver­sial pitch for ad­u­canum­ab

Last year
FDA+

An ‘in­no­cent by­stander’ in the boom­ing biotech in­vestor world is writ­ing a blank check for $100M. Who’s go­ing to cash it?

Last year
Financing

PS: Did any­one at Bio­gen ask the FDA to pull an ad­u­canum­ab con­sci­en­tious ob­jec­tor off their ex­pert pan­el? ‘No com­ment’

Last year
R&D
FDA+

Bris­tol My­ers wins a big bet as their PhI­II au­toim­mune drug beat out block­buster Ote­zla — and that could cost Am­gen dear­ly

Last year
R&D

Can a dark­horse syn­thet­ic bi­ol­o­gy Covid-19 vac­cine one-up the fron­tun­ners? The Gates Foun­da­tion, Am­gen bet 'yes'

Last year
R&D
Coronavirus

Bio­gen dodges a bul­let in its con­tro­ver­sial quest to gain an ap­proval for their ex­per­i­men­tal Alzheimer’s drug ad­u­canum­ab

Last year
FDA+

Re­gen­eron slams the brakes on rare dis­ease tri­al fol­low­ing pa­tient deaths — cast­ing more doubt on a drug with mixed re­sults

Last year
R&D

Joe Jimenez has one more thing to do in bio­phar­ma. And now he and Mark Fish­man have a $133M stake to play the start­up game

Last year
Financing
Deals

Sanofi’s Paul Hud­son pays $357M to buy a biotech part­ner, adding an NK strat­e­gy in the lat­est move to beef up can­cer R&D

Last year
R&D

In a sec­ond big set­back for Covid-19 an­ti­body treat­ment hopes, Re­gen­eron halts en­roll­ment for more se­vere pa­tients

Last year
R&D
Coronavirus

In ear­ly blow to Ken­ji Ya­sukawa's R&D re­vamp, Astel­las drops out of the TIG­IT race, cit­ing PhI fail­ure

Last year
R&D
First page Previous page 112113114115116117118 Next page Last page